<DOC>
	<DOCNO>NCT00225173</DOCNO>
	<brief_summary>Patients 3 adverse prognostic factor higher relapse rate . Significant anti-tumor activity Hodgkin 's lymphoma report two new drug : gemcitabine vinorelbine . The introduction new agent different mechanism action Stanford V regimen may increase effectiveness maintain favorable toxicity profile respect fertility low risk secondary leukemia . On basis , propose new regimen , Stanford VI , patient bulky advanced HD 3 risk factor .</brief_summary>
	<brief_title>Combination Chemotherapy +/- Radiation High Risk Hodgkin 's Disease</brief_title>
	<detailed_description>Patients receive chemotherapy weekly 19 week , alone follow irradiation indicate per protocol guideline . - Doxorubicin 25 mg/m2 IV w 1,3,5,7,9,11 - Vinblastine 6 mg/m2 IV w 1,3,5,7,9,11 - Cyclophosphamide 750 mg/m2 IV w 1 , 5 , 9 - Etoposide2 60 mg/mg2 x 2 IV w 3 , 7,11 - Vincristine1 1.4 mg/m2 IV w 2,4,6,8,10,12 ( cap @ 2mg ) - Bleomycin 5 u/m2 IV w 2,4,6,8,10,12 - Gemcitabine 1250 mg/m2 IV w 13,15,17,19 - Vinorelbine 25 mg/m2 IV w 13,15,17,19 - Prednisone 40 mg/m2 PO qod w 1-10 , taper</detailed_description>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Untreated , locally extensive advanced stage classical Hodgkin 's disease 3 adverse risk factor Age &gt; 18 year &lt; 70 year . No prior invasive malignancy &gt; 5 year except curativelytreated basal cell squamous cell carcinoma skin carcinoma situ cervix . ECOG performance status 0 2 WBC &gt; 4000/µL Platelets &gt; 100,000/µL Creatinine &lt; 2.0mg/dL Bilirubin &lt; 5.0mg/dL HIVpositive Pregnant currently breast feed woman Lymphocyte predominant Hodgkin 's disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>nodular sclerosis</keyword>
	<keyword>lymphocyte rich</keyword>
	<keyword>lymphocyte deplete</keyword>
	<keyword>mixed cellularity</keyword>
</DOC>